C.jpg c_ph.jpg
Pipeline
Ophthalmology

We aim to develop innovative disease-modifying therapeutics to preserve and improve patients’ vision.  The strength of our ophthalmology pipeline derives from our strong clinical development capability and close collaboration with industry and academic partners coupled with our deep scientific knowledge of diseases affecting the eye. 

With a diverse portfolio of drugs and drug candidates at different stages of development, we are focused on bringing patients safe and effective, best-in-class therapeutics for a spectrum of ophthalmic diseases in both the front and the back of the eye. The ophthalmic disease states we are targeting all are underserved clinically, with significant unmet medical needs in Greater China and other Asian countries.

Program Lead Indication AffaMed Territory Pre-clinical/IND Phase I Phase II Phase III Approved
AM007
Dextenza

Detail

Post surgical pain/infl, AC Greater China, Korea, SEA
AM008
OTX-TIC

Detail

Glaucoma Greater China, Korea, SEA
IOLs

Detail

Cataract Greater China
AM305
AG-73305

Detail

DME, nAMD, RVO Greater China, South Korea & SEA
AM002
SB11/Ranibizumab

Detail

wAMD, DME, RVO Mainland China, Singapore
AM003
SB15/Aflibercept

Detail

wAMD, DME Mainland China, Singapore
AM007
Dextenza

Read More

Lead Indication
Post surgical pain/infl, AC
AffaMed Territory
Greater China, Korea, SEA
Pre-clinical/IND Phase I Phase II Phase III Approved
AM008
OTX-TIC

Read More

Lead Indication
Glaucoma
AffaMed Territory
Greater China, Korea, SEA
Pre-clinical/IND Phase I Phase II Phase III Approved
IOLs

Read More

Lead Indication
Cataract
AffaMed Territory
Greater China
Pre-clinical/IND Phase I Phase II Phase III Approved
AM305
AG-73305

Read More

Lead Indication
DME, nAMD, RVO
AffaMed Territory
Greater China, South Korea & SEA
Pre-clinical/IND Phase I Phase II Phase III Approved
AM002
SB11/Ranibizumab

Read More

Lead Indication
wAMD, DME, RVO
AffaMed Territory
Mainland China, Singapore
Pre-clinical/IND Phase I Phase II Phase III Approved
AM003
SB15/Aflibercept

Read More

Lead Indication
wAMD, DME
AffaMed Territory
Mainland China, Singapore
Pre-clinical/IND Phase I Phase II Phase III Approved
Neurology & Psychiatry

We focus on neurology & psychiatry therapeutic areas with high unmet medical needs and great market potential.

Our partnerships with Chinese and global biopharmaceutical companies enhance our portfolio of innovative drug candidates in neurological and psychiatric diseases like Parkinson’s Disease (AD), social anxiety disorder (SAD), myasthenia gravis and ophthalmoneuromyelitis.


Program Lead Indication AffaMed Territory Pre-clinical/IND Phase I Phase II Phase III Approved
AM004
SB12/Eculizumab

Detail

PNH, aHUS, gMG, NMOSD Mainland China, Singapore
AM005
PH94B

Detail

Social anxiety disorder Greater China, Korea, SEA
AM006
KDT-3594

Detail

Parkinson’s disease Greater China, SEA
AM004
SB12/Eculizumab

Read More

Lead Indication
PNH, aHUS, gMG, NMOSD
AffaMed Territory
Mainland China, Singapore
Pre-clinical/IND Phase I Phase II Phase III Approved
AM005
PH94B

Read More

Lead Indication
Social anxiety disorder
AffaMed Territory
Greater China, Korea, SEA
Pre-clinical/IND Phase I Phase II Phase III Approved
AM006
KDT-3594

Read More

Lead Indication
Parkinson’s disease
AffaMed Territory
Greater China, SEA
Pre-clinical/IND Phase I Phase II Phase III Approved
Program:
Partner: